KLOTHO NEUROSCIENCES INC (KLTO) Stock Overview
USA - NASDAQ:KLTO - US49876K1034 - Common Stock
KLTO Key Statistics, Chart & Performance
The current stock price of KLTO is 0.5246 USD. In the past month the price increased by 8.25%. In the past year, price increased by 25.2%.
KLTO Latest News, Press Relases and Analysis
KLTO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.49 | 401.96B | ||
| AMGN | AMGEN INC | 13.39 | 157.25B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 146.27B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.93 | 108.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.34 | 69.37B | ||
| ARGX | ARGENX SE - ADR | 90.81 | 51.50B | ||
| INSM | INSMED INC | N/A | 34.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.80B | ||
| NTRA | NATERA INC | N/A | 26.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.25B | ||
| BIIB | BIOGEN INC | 9.31 | 21.86B |
Related stock screener links
About KLTO
Company Profile
Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in Omaha, Nebraska and currently employs 3 full-time employees. The company went IPO on 2022-04-29. The firm's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The firm's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).
Company Info
KLOTHO NEUROSCIENCES INC
13576 Walnut Street, Suite A
Omaha NEBRASKA US
Employees: 3
Phone: 18339316330
KLOTHO NEUROSCIENCES INC / KLTO FAQ
What does KLOTHO NEUROSCIENCES INC do?
Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in Omaha, Nebraska and currently employs 3 full-time employees. The company went IPO on 2022-04-29. The firm's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The firm's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).
Can you provide the latest stock price for KLOTHO NEUROSCIENCES INC?
The current stock price of KLTO is 0.5246 USD. The price decreased by -3.71% in the last trading session.
Does KLTO stock pay dividends?
KLTO does not pay a dividend.
How is the ChartMill rating for KLOTHO NEUROSCIENCES INC?
KLTO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for KLTO stock?
KLOTHO NEUROSCIENCES INC (KLTO) currently has 3 employees.
What is the ownership structure of KLOTHO NEUROSCIENCES INC (KLTO)?
You can find the ownership structure of KLOTHO NEUROSCIENCES INC (KLTO) on the Ownership tab.
KLTO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KLTO. When comparing the yearly performance of all stocks, KLTO is a bad performer in the overall market: 82.18% of all stocks are doing better.
KLTO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KLTO. No worries on liquidiy or solvency for KLTO as it has an excellent financial health rating, but there are worries on the profitability.
KLTO Financial Highlights
Over the last trailing twelve months KLTO reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by -1684.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -104.68% | ||
| ROE | -106.6% | ||
| Debt/Equity | 0 |